Format

Send to

Choose Destination
J Immunol. 2017 Jun 1;198(11):4205-4209. doi: 10.4049/jimmunol.1602131. Epub 2017 Apr 21.

Cutting Edge: A Dual TLR2 and TLR7 Ligand Induces Highly Potent Humoral and Cell-Mediated Immune Responses.

Author information

1
InvivoGen, 31400 Toulouse, France.
2
Laboratoire de Biologie Tissulaire et d'Ingénierie Thérapeutique, UMR5305, Université Lyon 1, CNRS, 69007 Lyon, France.
3
Groupe Immunité des Muqueuses et Agents Pathogènes, Faculté de Médecine de Saint-Etienne, INSERM Centre d'Investigation Clinique en Vaccinologie 1408, 42023 Saint-Etienne, France.
4
Sorbonne Universités, Université Pierre et Marie Curie - Université Paris VI, Departement Hospitalo-Universitaire "Vieillissement Immunitaire et Stress," Centre d'Immunologie et des Maladies Infectieuses, 75252 Paris, France.
5
INSERM U1135, Centre d'Immunologie et des Maladies Infectieuses, 75252 Paris, France.
6
Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff CF14 4XN, United Kingdom; and.
7
International Research Center of Medical Sciences, Kumamoto University, Kumamoto 860-0811, Japan.
8
Groupe Immunité des Muqueuses et Agents Pathogènes, Faculté de Médecine de Saint-Etienne, INSERM Centre d'Investigation Clinique en Vaccinologie 1408, 42023 Saint-Etienne, France; stephane.paul@chu-st-etienne.fr.

Abstract

TLR agonists are currently being developed and tested as adjuvants in various formulations to optimize the immunogenicity and efficacy of vaccines. The aim of this study was to evaluate the immunostimulatory properties of a novel compound incorporating covalently linked moieties designed to stimulate both TLR2 and TLR7. This dual TLR2/TLR7 agonist induced the maturation of dendritic cells and primed substantial populations of cytolytic and highly polyfunctional effector CD8+ T cells in vitro, and safely potentiated the immunogenic properties of a nanoparticulate Ag in vivo, eliciting humoral responses with a balanced TH1/TH2 profile in mice. Collectively, these data reveal the potential utility of chimeric adjuvants with synergistic activities mediated via TLRs.

PMID:
28432147
DOI:
10.4049/jimmunol.1602131
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center